Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial-Reference-Cited by-同舟云学术

Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial

Published:2008-01 Issue:1 Volume:9 Page:23-28
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Rasmussen Birgitte B,Regan Meredith M,Lykkesfeldt Anne E,Dell'Orto Patrizia,Del Curto Barbara,Henriksen Katrine L,Mastropasqua Mauro G,Price Karen N,Méry Eliane,Lacroix-Triki Magali,Braye Stephen,Altermatt Hans J,Gelber Richard D,Castiglione-Gertsch Monica,Goldhirsch Aron,Gusterson Barry A,Thürlimann Beat,Coates Alan S,Viale Giuseppe

Publisher

Elsevier BV

Subject

Oncology

Reference16 articles.

1. Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene;Slamon;Science,1987

2. HER-2/neu oncogene protein and prognosis in breast cancer;Tandon;J Clin Oncol,1989

3. Prognostic importance of c-erbB-2 expression in breast cancer;Gusterson;J Clin Oncol,1992

4. HER2 and response to paclitaxel in node-positive breast cancer;Hayes;N Engl J Med,2007

5. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer;Wolff;Arch Pathol Lab Med,2007

Cited by 137 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of first-line therapy in patients with HER2-positive advanced breast cancer: a network meta-analysis of randomized controlled trials;Journal of Cancer Research and Clinical Oncology;2024-01

2. Targeted Approaches to HER2-Low Breast Cancer: Current Practice and Future Directions;Cancers;2022-08-03

3. Human epidermal growth factor receptor-2 and endocrine resistance in hormone-dependent breast cancer;Endocrine-Related Cancer;2022-08-01

4. Long-Term Survival Outcomes of Patients with Small (≤ 1 Centimetre) Node-Negative HER2-Positive Breast Cancer Not Treated with Adjuvant Anti-HER2-Targeted Therapy: A 10-Year Follow-Up Study;Breast Care;2021-11-09

5. Solving current dilemmas in the adjuvant endocrine treatment of pre- and perimenopausal women with an estrogen receptor positive breast cancer;European Journal of Gynaecological Oncology;2021